Elicio Therapeutics Inc (ELTX) FinancialsELTXElicio Therapeutics Inc

Evaluating the bottom line, Elicio Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -774.56%, provide a clear picture of how effectively ELTX converts its operational activities into shareholder value.

In the context of the broader market, ELTX competes directly with industry leaders such as CRBU and TIL. With a market capitalization of $40.36M, it holds a significant position in the sector. When comparing efficiency, ELTX's gross margin of N/A stands against CRBU's 100.00% and TIL's N/A. Such benchmarking helps identify whether Elicio Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has reported consistent net income losses, with Q4 2024 showing a loss of $14 million and a gross profit of $0.00 in the same quarter. The current ratio is healthy at 2.77, indicating good short-term financial health, but the overall financial performance remains weak due to ongoing losses.